Corcept Therapeutics CORT
$63.62 −$1.36 (-2.09%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $63.62 0.00%
Open$64.07
Prev close$64.98
Day range$62.81 – $65.13
Volume1.09M
Market cap$6.96B
P/E (TTM)47.8
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$340.47M+64.0% YoY
Operating profit$114.72M+1,022.7% YoY
Net profit$126.78M+544.6% YoY
Diluted EPS$1.01+531.3% YoY
Free cash flow$142.18M+161.0% YoY
Operating cash flow$142.89M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Gross margin98.5%
Operating margin11.5%
Net margin16.5%
Return on equity21.7%
Return on assets17.2%
Return on invested capital19.9%
Current ratio3.00
Liabilities / assets19.4%
Cash & investments$370.70M
Total debt$6.97M
Net cash (debt)$363.74M
Free cash flow / sales20.2%
Where the revenue comes from
Quarter 2026/Q2
By business line
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Revenue as Reported | $340.47M | $256.15M | $164.90M | $761.41M | $202.13M |
| Total Operating Revenue | $340.47M | $256.15M | $164.90M | $761.41M | $202.13M |
| Cost of Revenue | $4.61M | $4.06M | $2.88M | $12.98M | $2.55M |
| Gross Profit | $335.86M | $252.09M | $162.02M | $748.43M | $199.58M |
| Operating Expense | $221.14M | $210.79M | $211.62M | $703.63M | $195.09M |
| Selling and Admin Expenses | $164.43M | $156.90M | $145.36M | $448.73M | $130.24M |
| Research & Development | $56.71M | $53.89M | $66.27M | $254.91M | $64.86M |
| Operating Profit | $114.72M | $41.30M | -$49.60M | $44.80M | $4.49M |
| Net Non-Operating Interest Income (Expense) | $5.58M | $4.63M | $4.89M | $21.67M | $5.42M |
| Non-Operating Interest Income | $5.58M | $4.63M | $4.89M | $21.67M | $5.42M |
| Pretax Profit | $120.31M | $45.93M | -$44.72M | $66.46M | $9.91M |
| Tax | -$6.47M | $2.94M | -$12.95M | -$33.19M | -$14.38M |
| Net Profit | $126.78M | $42.99M | -$31.76M | $99.65M | $24.29M |
| Profit from Continuing Operations | $126.78M | $42.99M | -$31.76M | $99.65M | $24.29M |
| Net Income to Parent Company | $126.78M | $42.99M | -$31.76M | $99.65M | $24.29M |
| Net Income to Common Stockholders | $124.49M | $42.14M | -$31.20M | $98.17M | $23.90M |
| Basic EPS | $1.17 | $0.40 | -$0.30 | $0.95 | $0.23 |
| Diluted EPS | $1.01 | $0.36 | -$0.30 | $0.82 | $0.20 |
| Other Preferred Stock Dividends | – | – | -$559,000.00 | $1.48M | – |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $1.03B | $888.70M | $814.88M | $836.65M | $836.65M |
| Total Current Assets | $533.87M | $439.68M | $426.03M | $485.46M | $485.46M |
| Cash and Cash Equivalents & Short-Term Investments | $370.70M | $308.20M | $338.18M | $372.15M | $372.15M |
| -Cash and Cash Equivalents | $98.72M | $111.04M | $108.74M | $120.50M | $120.50M |
| -Short Term Investments | $271.98M | $197.16M | $229.45M | $251.66M | $251.66M |
| Receivables | $111.06M | $76.92M | $39.07M | $59.79M | $59.79M |
| -Accounts Receivable | $111.06M | $76.92M | $39.07M | $59.79M | $59.79M |
| Prepaid Assets | $26.93M | $28.59M | $25.10M | $28.50M | $28.50M |
| Inventory | $11.91M | $13.19M | $12.89M | $12.87M | $12.87M |
| Current Deferred Assets | $6.07M | $4.43M | $4.41M | $5.06M | $5.06M |
| Other Current Assets | $7.21M | $8.36M | $6.38M | $7.10M | $7.10M |
| Total Non-Current Assets | $500.15M | $449.03M | $388.85M | $351.19M | $351.19M |
| Net PPE | $11.46M | $11.99M | $10.37M | $6.47M | $6.47M |
| -Gross PPE | $11.46M | $11.99M | $10.37M | $6.47M | $6.47M |
| Investments and Advances | $291.60M | $236.45M | $177.26M | $160.27M | $160.27M |
| -Available for Sale Securities | $291.60M | $236.45M | $177.26M | $160.27M | $160.27M |
| Non-Current Deferred Assets | $169.07M | $178.68M | $181.56M | $168.20M | $168.20M |
| Other Non-Current Assets | $28.02M | $21.90M | $19.66M | $16.25M | $16.25M |
| Total Liabilities | $200.29M | $182.93M | $176.89M | $188.85M | $188.85M |
| Total Current Liabilities | $177.68M | $153.80M | $149.19M | $166.09M | $166.09M |
| Payables | $21.92M | $14.91M | $33.31M | $40.44M | $40.44M |
| -Accounts Payable | $21.92M | $14.91M | $33.31M | $40.44M | $40.44M |
| Current Accrued Expenses | $39.42M | $38.12M | $47.68M | $44.56M | $44.56M |
| Short-Term Debt and Capital Lease Obligation | $2.02M | $1.92M | $1.63M | $1.08M | $1.08M |
| -Current Capital Lease Obligation | $2.02M | $1.92M | $1.63M | $1.08M | $1.08M |
| Current Deferred Liabilities | $52.50M | $45.85M | $33.56M | $35.68M | $35.68M |
| Other Current Liabilities | $9.05M | $14.75M | $12.14M | $6.91M | $6.91M |
| Total Non-Current Liabilities | $22.61M | $29.12M | $27.71M | $22.76M | $22.76M |
| Long Term Accounts Payable and Other Payables | $15.65M | $15.49M | $15.33M | $15.18M | $15.18M |
| Non-Current Accrued Expenses | $0.00 | $6.13M | $4.37M | $2.56M | $2.56M |
| Long Term Debt and Capital Lease Obligation | $6.97M | $7.50M | $8.01M | $5.02M | $5.02M |
| -Long Term Capital Lease Obligation | $6.97M | $7.50M | $8.01M | $5.02M | $5.02M |
| Total Equity | $833.74M | $705.78M | $637.99M | $647.81M | $647.81M |
| Stockholders' Equity | $833.74M | $705.78M | $637.99M | $647.81M | $647.81M |
| Capital Stock | $144,000.00 | $142,000.00 | $141,000.00 | $140,000.00 | $140,000.00 |
| -Common Stock | $144,000.00 | $142,000.00 | $141,000.00 | $140,000.00 | $140,000.00 |
| -Preferred Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Additional Paid-In Capital | $1.12B | $1.05B | $1.00B | $968.60M | $968.60M |
| Retained Earnings | $781.39M | $654.61M | $611.63M | $643.39M | $643.39M |
| Less: Treasury Stock | -$1.07B | -$998.01M | -$976.69M | -$966.59M | -$966.59M |
| Gains/Losses Not Affecting Retained Earnings | -$1.51M | $436,000.00 | $918,000.00 | $2.26M | $2.26M |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | $142.89M | $33.54M | -$16.77M | $142.00M | $38.45M |
| Net cash flow from continuing operations | $142.89M | $33.54M | -$16.77M | $142.00M | $38.45M |
| Net Income from Continuing Operations | $126.78M | $42.99M | -$31.76M | $99.65M | $24.29M |
| Depreciation & Depletion & Amortization | $1.03M | $863,000.00 | $598,000.00 | $1.89M | $482,000.00 |
| Deferred Tax | $9.61M | $2.88M | -$13.11M | -$37.54M | -$15.18M |
| Change in Working Capital | -$23.25M | -$41.90M | $5.29M | -$1.41M | $9.19M |
| -Change in Receivables | -$34.14M | -$37.85M | $20.71M | -$5.81M | $9.84M |
| -Change in Inventory | -$5.06M | -$4.26M | -$3.27M | -$7.48M | $483,000.00 |
| -Change in Prepaid Assets | $1.06M | -$3.40M | $4.74M | -$18.92M | -$1.79M |
| -Change in Payables and Accrued Expense | $14.90M | $3.61M | -$16.88M | $30.17M | $16,000.00 |
| Net cash flow from investing | -$131.99M | -$29.24M | $4.54M | $69.76M | -$11.84M |
| Net Cash Flow from Continuing Investing Activities | -$131.99M | -$29.24M | $4.54M | $69.76M | -$11.84M |
| Net PPE Purchase and Sale | -$709,000.00 | -$2.53M | -$201,000.00 | -$211,000.00 | -$50,000.00 |
| Net Investment Purchase and Sale | -$131.28M | -$26.71M | $4.74M | $69.97M | -$11.79M |
| Financing Cash Flow | -$23.89M | -$2.04M | $760,000.00 | -$220.37M | -$31.22M |
| Net Cash Flow from Continuing Financing Activities | -$23.89M | -$2.04M | $760,000.00 | -$220.37M | -$31.22M |
| Proceeds from Stock Option Exercised | $14.06M | $9.42M | $6.52M | -$147.43M | $5.32M |
| Net Other Financing Charges | -$37.95M | -$11.46M | -$5.76M | -$72.94M | -$36.54M |
| Ending Cash Balance | $99.39M | $112.29M | $109.99M | $120.50M | $120.50M |
| Net Change in Cash | -$12.98M | $2.26M | -$11.47M | -$8.61M | -$4.61M |
| Beginning Cash Balance | $112.29M | $109.99M | $121.75M | $127.67M | $126.14M |
| Effect of Exchange Rate Changes | $78,000.00 | $37,000.00 | -$287,000.00 | $1.44M | -$32,000.00 |
| Free Cash Flow | $142.18M | $31.02M | -$16.97M | $141.79M | $38.40M |
| -Change in Other Current Assets | – | – | – | $1.46M | $2.90M |
| -Change in Other Current Liabilities | – | – | – | -$829,000.00 | -$251,000.00 |
| Net Common Stock Issuance | – | – | – | $0.00 | – |
No comments yet — be the first to weigh in on CORT.
Sign in to join the discussion.